key: cord-0979168-y0dzbm2f
authors: Merhy, R.; Sarkis, A.‐S.; Kaikati, J.; El Khoury, L.; Ghosn, S.; Stephan, F.
title: New‐onset cutaneous lichen planus triggered by COVID‐19 vaccination
date: 2021-07-24
journal: J Eur Acad Dermatol Venereol
DOI: 10.1111/jdv.17504
sha: ffb7deabc2c2d6984e87ed5bf769407883775eb4
doc_id: 979168
cord_uid: y0dzbm2f

As the worldwide vaccination campaign against the COVID-19 pandemic continues, cutaneous manifestations are being increasingly reported as adverse events of the different approved COVID-19 vaccines for emergency use. 1,2 Delayed large local reactions were the most commonly reported cutaneous adverse events, followed by other heterogeneous less common reactions such as urticarial or morbiliform eruptions, pernio/chilblains, and pityriasis rosea-like reactions3 . Although the cutaneous manifestations triggered by COVID-19 vaccines are rare, they appear similar to those reported during the pandemic as being related to the infection 2,4,5 .

To the Editor As the worldwide vaccination campaign against the COVID-19 pandemic continues, cutaneous manifestations are being increasingly reported as adverse events of the different approved COVID-19 vaccines for emergency use. 1,2 Delayed large local reactions were the most commonly reported cutaneous adverse events, followed by other heterogeneous less common reactions such as urticarial or morbilliform eruptions, pernio/chilblains and pityriasis rosea-like reactions. 3 Although the cutaneous manifestations triggered by COVID-19 vaccines are rare, they appear similar to those reported during the pandemic as being related to the infection. 2, 4, 5 Reports of lichen planus as a cutaneous manifestation of COVID-19 vaccination are scarce. 3 Recently, a flare of a pre-existing lichen planus has been reported following Pfizer vaccine. 6 Herein, we report a case of a new-onset lichen planus triggered by the Pfizer-BioNTech COVID-19 vaccine.

A 56-year-old woman, with no significant past medical history, presented to our department for a 1-week history of intense pruritic eruption. The lesions had appeared one week after the first dose of the Pfizer-BioNTech COVID-19 vaccine. On the physical examination, erythematous and squamous papules were found predominantly on the trunk, with visible Wickham's striae on dermoscopy (Fig. 1) . No mucosal involvement was noted. A skin biopsy was performed, showing compact hyperkeratosis, hypergranulosis, irregular epidermal hyperplasia and a moderately dense lichenoid lymphocytic infiltrate (Fig. 2a) , with the presence of scarce eosinophils in the dermis (Fig. 2b) . In view of the clinical picture, the timing of the skin eruption with respect to the vaccine and the histopathologic findings, a druginduced lichen planus triggered by the COVID-19 vaccine has been diagnosed.

Lichen planus had been frequently associated with different infections, medications and vaccines including HBV vaccination. 7 This is a rare case of new-onset lichen planus arising after the COVID-19 vaccination. The vaccination induces a Th1 cell response and a subsequent various cytokines secretion that may play a key role in the development of this condition. 6 The exact pathogenesis is yet to be uncovered.

Dermatologists have a crucial role in the diagnosis of cutaneous complications related to COVID-19 vaccination. Nevertheless, these adverse events and others should not discourage vaccination against a life-threatening virus.

Cutaneous adverse reactions after m-RNA COVID-19 vaccine: early reports from Northeast Italy

Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases

Pityriasis rosea as a leading manifestation of COVID-19 infection

Cutaneous manifestations in SARS-CoV-2 infection (COVID-19): a French experience and a systematic review of the literature

Lichen planus arising after COVID-19 vaccination

Lichen planus: a comprehensive evidence-based analysis of medical treatment

H&E 9100): Microscopy shows compact hyperkeratosis, hypergranulosis, irregular epidermal hyperplasia and a moderately dense lichenoid lymphocytic infiltrate. (b) (H&E 9400): Given the presence of eosinophils (arrow) and parakeratosis a drug

The patient in this manuscript has given written informed consent to the publication of her case details